Platform trials

Platform trials focus on the perpetual testing of many interventions in a disease or a setting. These trials have lasting organizational, administrative, data, analytic, and operational frameworks making them highly efficient. The use of adaptation often increases the probabilities of allocating participants to better interventions and obtaining conclusive results. The COVID-19 pandemic showed the potential of platform trials as a fast and valid way to improved treatments. This review gives an overview of key concepts and elements using the Intensive Care Platform Trial (INCEPT) as an example.</p

Market integration of wind power in electricity system balancing

In most countries markets for electricity are divided into wholesale markets on which electricity is traded before the operation hour, and real-time balancing markets to handle the deviations from the wholesale trading. So far, wind power has been sold only on the wholesale market and has been known to increase the need for balancing. This article analyses whether wind turbines in the future should participate in the balancing markets and thereby play a proactive role. The analysis is based on a real-life test of proactive participation of a wind farm in West Denmark. It is found that the wind farm is able to play a proactive role regarding downward regulation and thereby increase profits. Keywords: Electricity market, Balancing service, Wind power integratio

Patient-Important Outcomes Other Than Mortality in Contemporary ICU Trials:A Scoping Review

This upload contains the final datasets analyzed in the manuscript "Patient-Important Outcomes Other Than Mortality in Contemporary ICU Trials: A Scoping Review", published in Critical Care Medicine, 2022 (https://doi.org/10.1097/CCM.0000000000005637). The Supplemental Digital Content included with the primary manuscript includes a data dictionary, additional details, and the analysis code used

Data for "Patient-Important Outcomes Other Than Mortality in Contemporary ICU Trials: A Scoping Review"

This upload contains the final datasets analyzed in the manuscript "Patient-Important Outcomes Other Than Mortality in Contemporary ICU Trials: A Scoping Review", published in Critical Care Medicine, 2022 (https://doi.org/10.1097/CCM.0000000000005637). The Supplemental Digital Content included with the primary manuscript includes a data dictionary, additional details, and the analysis code used

Systematic review of quantitative imaging biomarkers for neck and shoulder musculoskeletal disorders

© 2017 The Author(s). Background: This study systematically summarizes quantitative imaging biomarker research in non-traumatic neck and shoulder musculoskeletal disorders (MSDs). There were two research questions: 1) Are there quantitative imaging biomarkers associated with the presence of neck and shoulder MSDs?, 2) Are there quantitative imaging biomarkers associated with the severity of neck and shoulder MSDs? Methods: PubMed and SCOPUS were used for the literature search. One hundred and twenty-five studies met primary inclusion criteria. Data were extracted from 49 sufficient quality studies. Results: Most of the 125 studies were cross-sectional and utilized convenience samples of patients as both cases and controls. Only half controlled for potential confounders via exclusion or in the analysis. Approximately one-third reported response rates. In sufficient quality articles, 82% demonstrated at least one statistically significant association between the MSD(s) and biomarker(s) studied. The literature synthesis suggested that neck muscle size may be decreased in neck pain, and trapezius myalgia and neck/shoulder pain may be associated with reduced vascularity in the trapezius and reduced trapezius oxygen saturation at rest and in response to upper extremity tasks. Reduced vascularity in the supraspinatus tendon may also be a feature in rotator cuff tears. Five of eight studies showed an association between a quantitative imaging marker and MSD severity. Conclusions: Although research on quantitative imaging biomarkers is still in a nascent stage, some MSD biomarkers were identified. There are limitations in the articles examined, including possible selection bias and inattention to potentially confounding factors. Recommendations for future studies are provided